Mereo BioPharma Group plc

Mereo BioPharma Group plc held its 2026 Annual General Meeting of Shareholders on May 14, 2026, where all proposed resolutions were passed. Shareholders approved the annual report and accounts, re-appointed PricewaterhouseCoopers LLP as auditors, and authorized the Audit and Risk Committee to determine auditor remuneration. Additionally, the directors' remuneration report and policy were approved, along with the compensation of named executive officers on an advisory basis. Shareholders also re-elected three directors and authorized the directors to allot shares and allot shares for cash on a non-pre-emptive basis.

Mereo BioPharma Group plc reported a significant reduction in its net loss for the first quarter of 2026, which decreased to $6.7 million from $12.9 million in the prior year. This improvement was primarily driven by lower general and administrative expenses and a favorable foreign currency transaction gain. The company ended the quarter with $36.2 million in cash and cash equivalents, down from $41.0 million at year-end 2025, and expects this to fund operations for at least 12 months.

Mereo BioPharma reported a reduced net loss of $6.7 million for Q1 2026, down from $12.9 million in Q1 2025. The company and its partner Ultragenyx are engaging regulatory agencies to determine a path forward for setrusumab in pediatric osteogenesis imperfecta, despite Phase 3 studies not meeting primary endpoints but showing significant improvements in secondary endpoints. Mereo is also actively seeking partners for alvelestat's Phase 3 development and expects its cash of $36.2 million to fund operations into mid-2027.

Mereo BioPharma reported a net loss of $6.7 million for the first quarter ended March 31, 2026, a significant reduction from $12.9 million in Q1 2025. The company held $36.2 million in cash and cash equivalents, projecting a cash runway into mid-2027. Key clinical updates include initiating regulatory discussions for setrusumab in pediatric patients following positive secondary endpoint data from Phase 3 studies, active partnership discussions for alvelestat's Phase 3 development, and partner āshibio's plan to start a Phase 2 trial for vantictumab in the second half of 2026.